Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease

NCT07205601 is registered in ClinicalTrials.gov with Regeneration Biomedical, Inc. as lead sponsor.

NCT NCT07205601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease
Lead sponsor
Regeneration Biomedical, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
February 28, 2030
Enrollment
115 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease